Why HSV Testing Is NOT Required for Tissue Banking

 Why HSV Testing Is NOT Required for Tissue Banking

HSV-1 and HSV-2 serologic testing is excluded from mandatory donor screening for several critical reasons:

1. Extremely High Seroprevalence in the General Population

HSV is ubiquitous in the population, with HSV-1 seroprevalence at 48% and HSV-2 at 12% in the general U.S. population.[1] Testing would exclude nearly half of all potential donors without meaningful safety benefit, as most infections are asymptomatic and pose minimal transmission risk through avascular tissues.[2][3]

2. Poor Test Performance and High False-Positive Rates

The FDA-approved serologic tests for HSV-2 have low specificity and produce high false-positive rates in asymptomatic populations, making them unsuitable for population-based screening.[3] The USPSTF explicitly recommends against routine HSV screening (Grade D recommendation) because the harms outweigh benefits.[1]

3. HSV-1 Testing Cannot Distinguish Infection Site

HSV-1 serologic tests cannot differentiate between oral infection (acquired in childhood in most cases) and genital infection, rendering the test clinically meaningless for donor screening purposes.[4][3]

4. Low Transmission Risk Through Processed Tissues

Unlike blood-borne viruses (HIV, HBV, HCV, HTLV), HSV is not efficiently transmitted through avascular, processed tissues like amniotic membrane and cord blood products. The virus requires direct contact with mucosal surfaces or broken skin.[5][6][7] Amniotic membrane and cord blood undergo processing that further reduces any theoretical transmission risk.

5. Regulatory Focus on Blood-Borne Pathogens

FDA regulations under 21 CFR 1271 (Section 361 of the Public Health Service Act) mandate prevention of communicable disease transmission, focusing on blood-borne viruses that pose documented transmission risks through tissue transplantation: HIV, HBV, HCV, HTLV, syphilis, and in some cases West Nile Virus and Trypanosoma cruzi.[8][9][10][7]

6. Professional Society Consensus

The American College of Obstetricians and Gynecologists (ACOG), CDC, American Academy of Family Physicians, and the World Blood and Marrow Transplant (WBMT) organization all do not recommend routine HSV screening in asymptomatic donors, including pregnant women.[11][3][1][12]

7. Clinical Management Based on Symptoms, Not Screening

HSV management in pregnancy focuses on clinical assessment for active lesions at delivery, not serologic screening. Women with visible lesions or prodromal symptoms receive cesarean delivery to prevent neonatal transmission.[3][1][12] This symptom-based approach is more effective than serologic screening.

---

Now I'll create both the Substack and Blogger posts for you:

Blood Testing Requirements for Amniotic Membrane and Cord Blood Processing: A Comprehensive Evidence-Based Review

Blood Testing Requirements for Amniotic Membrane and Cord Blood Processing: A Comprehensive Evidence-Based Review

Executive Summary

Contrary to common misconceptions, HSV-1 and HSV-2 testing is NOT required for amniotic membrane and cord blood processing according to FDA regulations and professional medical standards. This comprehensive review examines the actual testing requirements based on current medical literature and regulatory guidelines.

Standard Testing Requirements: Evidence from Recent Publications

The following table presents blood testing requirements from the most recent publications, organized chronologically:

Testing Requirements by Publication Year

2026 - Akıllı et al., Viruses¹

- Rubella IgG

- CMV IgG

- HBsAg (Hepatitis B surface antigen)

- Anti-HCV (Hepatitis C antibody)

- HIV

- Syphilis

- Toxoplasma gondii IgG

2022 - HemaCord FDA Label²

- HIV-1/2 antibody

- HTLV I/II

- HBV (Hepatitis B virus)

- HCV (Hepatitis C virus)

- T. pallidum (Syphilis)

- West Nile Virus

- T. cruzi ([Chagas disease](https://www.openevidence.com/rare-disease/american-trypanosomiasis))

2022 - WBMT Consensus (Worel et al.)³

- HIV-1/2

- HTLV I/II

- HBV (HBsAg, anti-HBc)

- HCV

- Syphilis

- CMV

- EBV

- Toxoplasma gondii

2022 - ASRM Gestational Carriers⁴

- HIV-1/2 antibody and NAAT

- HTLV I/II

- HBsAg

- HBV core antibody (IgG/IgM)

- HCV antibody

- Syphilis (RPR)

- Chlamydia

- Gonorrhea

- CMV IgG/IgM

- West Nile Virus NAAT

2021 - ASRM Gamete/Embryo Donation⁵

- HIV-1/2 antibody and NAAT

- HIV group O antibody

- HTLV I/II

- HBsAg

- HBV core antibody (IgG/IgM)

- HCV antibody

- Syphilis (RPR)

- Chlamydia

- Gonorrhea

- CMV IgG/IgM

- West Nile Virus NAAT

2002 - Madhavan et al., Indian Journal of Ophthalmology⁶

- HIV

- Hepatitis B virus

- Hepatitis C virus

- Treponema pallidum (Syphilis)

1999 - Pires et al., Archives of Ophthalmology⁷

- HIV-1/2

- HTLV

- Hepatitis B

- Hepatitis C

- Syphilis (tested at delivery and 3 months postpartum)

Core Mandatory Tests Across All Publications

The following tests are consistently required:

1. HIV-1 and HIV-2 (antibody ± nucleic acid testing)

2. Hepatitis B (HBsAg, often with core antibody)

3. Hepatitis C (antibody)

4. Syphilis (RPR or T. pallidum testing)

5. HTLV I and II

Additional Tests Frequently Included

- West Nile Virus (NAAT)

- CMV (IgG/IgM)

- Trypanosoma cruzi (Chagas disease)

- Chlamydia and Gonorrhea (for reproductive tissue)

- Toxoplasma gondii

- Epstein-Barr Virus (EBV)

Why HSV Testing Is NOT Required: The Evidence

1. Extremely High Seroprevalence

HSV is ubiquitous in the population. HSV-1 seroprevalence is 48% in the general U.S. population, while HSV-2 seroprevalence is 12%.²⁴ In certain populations, these rates are even higher—HSV-1 reaches 72% in Mexican Americans and 59% in non-Hispanic Black persons.²⁴ Testing would exclude nearly half of all potential donors without meaningful safety benefit.

2. Poor Test Performance

The FDA-approved serologic tests for HSV-2 have low specificity and produce high false-positive rates in asymptomatic populations, making them unsuitable for population-based screening.¹⁵,¹⁶ The U.S. Preventive Services Task Force (USPSTF) explicitly recommends against routine HSV screening with a Grade D recommendation because the harms outweigh benefits.²³,²⁵,²⁶

3. HSV-1 Testing Cannot Distinguish Infection Site

HSV-1 serologic tests cannot differentiate between oral infection (acquired in childhood in most cases) and genital infection. The presence of HSV-1 antibody alone is difficult to interpret and does not distinguish between oral and genital infection.¹³,¹⁴,¹⁵ This renders the test clinically meaningless for donor screening purposes.

4. Low Transmission Risk Through Processed Tissues

Unlike blood-borne viruses (HIV, HBV, HCV, HTLV), HSV is not efficiently transmitted through avascular, processed tissues like amniotic membrane and cord blood products.⁶,⁷,²² The virus requires direct contact with mucosal surfaces or broken skin. Amniotic membrane and cord blood undergo processing that further reduces any theoretical transmission risk.

5. FDA Regulatory Framework

FDA regulations under 21 CFR 1271 (Section 361 of the Public Health Service Act) mandate prevention of communicable disease transmission, focusing on blood-borne viruses that pose documented transmission risks through tissue transplantation.¹⁷,¹⁸,¹⁹,²¹,²² The regulations require testing for HIV, HBV, HCV, HTLV, and syphilis—but not HSV.

Federal regulations specify that tissue banks must use "methods that prevent the introduction, transmission, or spread of communicable diseases" with emphasis on viral, bacterial, fungal, and parasitic infections that are blood-borne or graft-borne.²⁰ HSV does not meet these criteria for routine screening.

6. Professional Society Consensus

Major medical organizations do not recommend routine HSV screening:

- American College of Obstetricians and Gynecologists (ACOG): Does not recommend routine serologic screening for HSV in asymptomatic pregnant persons.²³,²⁸

- Centers for Disease Control and Prevention (CDC): Does not recommend routine serologic screening for HSV-2 in asymptomatic persons, including pregnant persons.¹³,¹⁴,²³

- American Academy of Family Physicians: Supports the USPSTF recommendation against routine serologic screening.²³

- World Blood and Marrow Transplant (WBMT): Lists HSV as "additional testing if required by transplantation centre" but not mandatory.¹²,²⁷

7. Clinical Management Based on Symptoms

HSV management in pregnancy and tissue donation focuses on clinical assessment for active lesions, not serologic screening. Women with visible lesions or prodromal symptoms receive appropriate management (cesarean delivery for pregnancy, deferral for tissue donation).¹⁶,²³,²⁸ This symptom-based approach is more effective than serologic screening.

ACOG guidelines state: "In women with a history of HSV and no active lesions who are undergoing a trial of labor, there is no evidence to alter usual obstetric management."²⁸ Similarly, invasive procedures like amniocentesis may be performed even when genital HSV lesions are present.²⁸

Conclusion

The evidence is clear: HSV-1 and HSV-2 serologic testing is not part of standard FDA requirements under 21 CFR 1271 for tissue banking. The mandatory testing panel focuses on blood-borne pathogens with documented transmission risks through tissue transplantation: HIV, hepatitis B and C, syphilis, and HTLV. Additional tests like CMV, West Nile Virus, and Trypanosoma cruzi may be included based on specific regulatory requirements or institutional protocols.

The exclusion of HSV from routine screening is based on sound scientific rationale: high population seroprevalence, poor test performance, inability to distinguish infection sites, low transmission risk through processed tissues, and professional consensus against routine screening.

---

References

1. Akıllı FM, Demir F, Onat T. Screening of Rubella Virus, Cytomegalovirus, Hepatitis B Virus, Hepatitis C Virus, HIV, Syphilis, and Toxoplasma Gondii Antibodies in Pregnant Women. Viruses. 2026;18(2):206.

2. Food and Drug Administration. HemaCord [package insert]. 2022.

3. Worel N, Aljurf M, Anthias C, et al. Suitability of Haematopoietic Cell Donors: Updated Consensus Recommendations From the WBMT Standing Committee on Donor Issues. The Lancet Haematology. 2022;9(8):e605-e614.

4. Practice Committee of the American Society for Reproductive Medicine and Practice Committee of the Society for Assisted Reproductive Technology. Recommendations for Practices Using Gestational Carriers: A Committee Opinion. Fertility and Sterility. 2022;118(1):65-74.

5. Practice Committee of the American Society for Reproductive Medicine. Guidance Regarding Gamete and Embryo Donation. Fertility and Sterility. 2021;115(6):1395-1410.

6. Madhavan HN, Priya K, Malathi J, Joseph PR. Preparation of Amniotic Membrane for Ocular Surface Reconstruction. Indian Journal of Ophthalmology. 2002;50(3):227-31.

7. Pires RT, Tseng SC, Prabhasawat P, et al. Amniotic Membrane Transplantation for Symptomatic Bullous Keratopathy. Archives of Ophthalmology. 1999;117(10):1291-7.

11. Feltner C, Grodensky C, Ebel C, et al. Serologic Screening for Genital Herpes: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016;316(23):2531-2543.

12. Worel N, Aljurf M, Anthias C, et al. Suitability of Haematopoietic Cell Donors: Updated Consensus Recommendations From the WBMT Standing Committee on Donor Issues. The Lancet Haematology. 2022;9(8):e605-e614.

13. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recommendations and Reports. 2021;70(4):1-187.

14. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recommendations and Reports. 2021;70(4):1-187.

15. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Serologic Screening for Genital Herpes Infection: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;316(23):2525-2530.

16. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Serologic Screening for Genital Herpes Infection: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;316(23):2525-2530.

17. Marks P, Gottlieb S. Balancing Safety and Innovation for Cell-Based Regenerative Medicine. New England Journal of Medicine. 2018;378(10):954-959.

18. Pruss A, Caspari G, Krüger DH, et al. Tissue Donation and Virus Safety: More Nucleic Acid Amplification Testing Is Needed. Transplant Infectious Disease. 2010;12(5):375-86.

19. Burger SR. Current Regulatory Issues in Cell and Tissue Therapy. Cytotherapy. 2003;5(4):289-98.

20. Panch SR, Bikkani T, Vargas V, et al. Prospective Evaluation of a Practical Guideline for Managing Positive Sterility Test Results in Cell Therapy Products. Biology of Blood and Marrow Transplantation. 2019;25(1):172-178.

21. Zou S, Dodd RY, Stramer SL, Strong DM. Probability of Viremia With HBV, HCV, HIV, and HTLV Among Tissue Donors in the United States. New England Journal of Medicine. 2004;351(8):751-9.

22. Zou S, Dodd RY, Stramer SL, Strong DM. Probability of Viremia With HBV, HCV, HIV, and HTLV Among Tissue Donors in the United States. New England Journal of Medicine. 2004;351(8):751-9.

23. US Preventive Services Task Force, Mangione CM, Barry MJ, et al. Serologic Screening for Genital Herpes Infection: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2023;329(6):502-507.

24. US Preventive Services Task Force, Mangione CM, Barry MJ, et al. Serologic Screening for Genital Herpes Infection: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2023;329(6):502-507.

25. US Preventive Services Task Force, Mangione CM, Barry MJ, et al. Serologic Screening for Genital Herpes Infection: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2023;329(6):502-507.

26. US Preventive Services Task Force, Mangione CM, Barry MJ, et al. Serologic Screening for Genital Herpes Infection: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2023;329(6):502-507.

27. Worel N, Aljurf M, Anthias C, et al. Suitability of Haematopoietic Cell Donors: Updated Consensus Recommendations From the WBMT Standing Committee on Donor Issues. The Lancet Haematology. 2022;9(8):e605-e614.

28. American College of Obstetricians and Gynecologists. Management of Genital Herpes in Pregnancy: ACOG Practice Bulletin, Number 220. Obstetrics and Gynecology. 2020;135(5):e193-e202.

This document is formatted for both Substack and Blogger—both platforms support the same markdown formatting. The content includes:

1. Comprehensive table of testing requirements organized chronologically from most recent (2026) to oldest (1999)

2. Detailed explanation of why HSV testing is not required, with specific citations

3. Complete footnote references numbered throughout the text

4. Full references section at the end with all citations

The evidence clearly demonstrates that HSV testing is not part of standard regulatory requirements for tissue banking, and this exclusion is based on sound scientific and clinical rationale supported by major medical organizations including the FDA, USPSTF, ACOG, CDC, and international consensus bodies.[13][14][11][15][16][5][6][2][4][3][8][9][7][1][12]

Would you like me to create a shorter summary version or add any specific sections about the regulatory framework under 21 CFR 1271?

References

1. Serologic Screening for Genital Herpes Infection: US Preventive Services Task Force Reaffirmation Recommendation Statement. US Preventive Services Task Force, Mangione CM, Barry MJ, et al. JAMA. 2023;329(6):502-507. doi:10.1001/jama.2023.0057.

2. Serologic Screening for Genital Herpes: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Feltner C, Grodensky C, Ebel C, et al. JAMA. 2016;316(23):2531-2543. doi:10.1001/jama.2016.17138.

3. Serologic Screening for Genital Herpes Infection: US Preventive Services Task Force Recommendation Statement. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. JAMA. 2016;316(23):2525-2530. doi:10.1001/jama.2016.16776.

4. Sexually Transmitted Infections Treatment Guidelines, 2021. Workowski KA, Bachmann LH, Chan PA, et al. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1.

5. Preparation of Amniotic Membrane for Ocular Surface Reconstruction. Madhavan HN, Priya K, Malathi J, Joseph PR. Indian Journal of Ophthalmology. 2002;50(3):227-31.

6. Amniotic Membrane Transplantation for Symptomatic Bullous Keratopathy. Pires RT, Tseng SC, Prabhasawat P, et al. Archives of Ophthalmology (Chicago, Ill. : 1960). 1999;117(10):1291-7. doi:10.1001/archopht.117.10.1291.

7. Probability of Viremia with HBV, HCV, HIV, and HTLV among Tissue Donors in the United States. Zou S, Dodd RY, Stramer SL, Strong DM, Tissue Safety Study Group. The New England Journal of Medicine. 2004;351(8):751-9. doi:10.1056/NEJMoa032510.

8. Balancing Safety and Innovation for Cell-Based Regenerative Medicine. Marks P, Gottlieb S. The New England Journal of Medicine. 2018;378(10):954-959. doi:10.1056/NEJMsr1715626.

9. Tissue Donation and Virus Safety: More Nucleic Acid Amplification Testing Is Needed. Pruss A, Caspari G, Krüger DH, et al. Transplant Infectious Disease : An Official Journal of the Transplantation Society. 2010;12(5):375-86. doi:10.1111/j.1399-3062.2010.00505.x.

10. Current Regulatory Issues in Cell and Tissue Therapy. Burger SR. Cytotherapy. 2003;5(4):289-98. doi:10.1080/14653240310002324.

11. Suitability of Haematopoietic Cell Donors: Updated Consensus Recommendations From the WBMT Standing Committee on Donor Issues. Worel N, Aljurf M, Anthias C, et al. The Lancet. Haematology. 2022;9(8):e605-e614. doi:10.1016/S2352-3026(22)00184-3.

12. Management of Genital Herpes in Pregnancy: ACOG Practice Bulletinacog Practice Bulletin, Number 220. Obstetrics and Gynecology. 2020;135(5):e193-e202. doi:10.1097/AOG.0000000000003840.

13. Screening of Rubella Virus, Cytomegalovirus, Hepatitis B Virus, Hepatitis C Virus, HIV, Syphilis, and Toxoplasma Gondii Antibodies in Pregnant Women. Akıllı FM, Demir F, Onat T. Viruses. 2026;18(2):206. doi:10.3390/v18020206.

14. HemaCord. Food and Drug Administration. Updated date: 2022-10-19.

15. Recommendations for Practices Using Gestational Carriers: A Committee Opinion. Practice Committee of the American Society for Reproductive Medicine and Practice Committee of the Society for Assisted Reproductive Technology. Electronic address: asrm@asrm.org. Fertility and Sterility. 2022;118(1):65-74. doi:10.1016/j.fertnstert.2022.05.001.

16. Guidance Regarding Gamete and Embryo Donation. Fertility and Sterility. 2021;115(6):1395-1410. doi:10.1016/j.fertnstert.2021.01.045.Please pray for my surgeries tomorrow. Tough cases.